KingCrab personal page - To The Moon

KingCrab

KingCrab

No personal profile

2Follow

0Followers

0Topic

0Badge

02-15

$DBS GROUP HOLDINGS LTD(D05.SI)$

2023-02-13

Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.

G1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial

2022-09-05

I'm still bullish with this stock. China's supply comes online? Disruption of supply chain occurs each time China has a military drill around Taiwan. Besides, just wait for the next pandemic and this stock will sky-rocket again.

Riverstone Holdings' Healthcare Gloves Segment Faces Headwinds -- Market Talk

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3562115684410726","uuid":"3562115684410726","gmtCreate":1599031339733,"gmtModify":1599032807460,"name":"KingCrab","pinyin":"kingcrab","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/405b64f3c681fc35136b02e8b5a53c12","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":"93.78%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":274081223147728,"gmtCreate":1707952270413,"gmtModify":1707958449219,"author":{"id":"3562115684410726","authorId":"3562115684410726","name":"KingCrab","avatar":"https://static.tigerbbs.com/405b64f3c681fc35136b02e8b5a53c12","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562115684410726","authorIdStr":"3562115684410726"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/D05.SI\">$DBS GROUP HOLDINGS LTD(D05.SI)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/D05.SI\">$DBS GROUP HOLDINGS LTD(D05.SI)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$DBS GROUP HOLDINGS LTD(D05.SI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/274081223147728","isVote":1,"tweetType":1,"viewCount":67,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9954633055,"gmtCreate":1676300342478,"gmtModify":1676302498607,"author":{"id":"3562115684410726","authorId":"3562115684410726","name":"KingCrab","avatar":"https://static.tigerbbs.com/405b64f3c681fc35136b02e8b5a53c12","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562115684410726","authorIdStr":"3562115684410726"},"themes":[],"htmlText":"Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.","listText":"Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.","text":"Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9954633055","repostId":"2311278989","repostType":2,"repost":{"id":"2311278989","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1676291924,"share":"https://ttm.financial/m/news/2311278989?lang=&edition=fundamental","pubTime":"2023-02-13 20:38","market":"us","language":"en","title":"G1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2311278989","media":"Dow Jones","summary":"G1 Therapeutics Inc. said it has decided to discontinue its Phase 3 trial, called Preserve 1, that t","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/GTHX\">G1 Therapeutics Inc.</a> said it has decided to discontinue its Phase 3 trial, called Preserve 1, that tested trilaciclib administered along with triplet therapy with Folfoxiri and bevacizumab in patients with metastatic colorectal cancer.</p><p>Shares fell 55% to $3.2 in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/058bf0f8b0deeb4381b26c96de767e1e\" tg-width=\"838\" tg-height=\"840\" width=\"100%\" height=\"auto\"/></p><p>The company said the trial achieved its co-primary endpoints showing clinically meaningful reductions in severe neutropenia during induction, as well as in the average duration of severe neutropenia. Patients treated with trilaciclib also showed a reduction in the rate of chemotherapy-induced diarrhea, the company said.</p><p>However, early anti-tumor efficacy data favored patients in the placebo arm of the trial, the company said.</p><p>&#34;All of us at G1 are disappointed in this surprising outcome for patients with CRC, but we remain committed to the potential of trilaciclib to impact the lives of many cancer patients in other indications,&#34; G1 Chief Executive Jack Bailey said. &#34;We are increasingly encouraged by the real-world performance of trilaciclib in patients with extensive stage small cell lung cancer and look forward to upcoming readouts in our other ongoing trials.&#34;</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>G1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nG1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-02-13 20:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/GTHX\">G1 Therapeutics Inc.</a> said it has decided to discontinue its Phase 3 trial, called Preserve 1, that tested trilaciclib administered along with triplet therapy with Folfoxiri and bevacizumab in patients with metastatic colorectal cancer.</p><p>Shares fell 55% to $3.2 in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/058bf0f8b0deeb4381b26c96de767e1e\" tg-width=\"838\" tg-height=\"840\" width=\"100%\" height=\"auto\"/></p><p>The company said the trial achieved its co-primary endpoints showing clinically meaningful reductions in severe neutropenia during induction, as well as in the average duration of severe neutropenia. Patients treated with trilaciclib also showed a reduction in the rate of chemotherapy-induced diarrhea, the company said.</p><p>However, early anti-tumor efficacy data favored patients in the placebo arm of the trial, the company said.</p><p>&#34;All of us at G1 are disappointed in this surprising outcome for patients with CRC, but we remain committed to the potential of trilaciclib to impact the lives of many cancer patients in other indications,&#34; G1 Chief Executive Jack Bailey said. &#34;We are increasingly encouraged by the real-world performance of trilaciclib in patients with extensive stage small cell lung cancer and look forward to upcoming readouts in our other ongoing trials.&#34;</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4191":"家用电器","GTHX":"G1 Therapeutics Inc.","BK4539":"次新股","BK4007":"制药","BK4139":"生物科技","CRCT":"Cricut, Inc.","TERN":"Terns Pharmaceuticals, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2311278989","content_text":"G1 Therapeutics Inc. said it has decided to discontinue its Phase 3 trial, called Preserve 1, that tested trilaciclib administered along with triplet therapy with Folfoxiri and bevacizumab in patients with metastatic colorectal cancer.Shares fell 55% to $3.2 in premarket trading.The company said the trial achieved its co-primary endpoints showing clinically meaningful reductions in severe neutropenia during induction, as well as in the average duration of severe neutropenia. Patients treated with trilaciclib also showed a reduction in the rate of chemotherapy-induced diarrhea, the company said.However, early anti-tumor efficacy data favored patients in the placebo arm of the trial, the company said.\"All of us at G1 are disappointed in this surprising outcome for patients with CRC, but we remain committed to the potential of trilaciclib to impact the lives of many cancer patients in other indications,\" G1 Chief Executive Jack Bailey said. \"We are increasingly encouraged by the real-world performance of trilaciclib in patients with extensive stage small cell lung cancer and look forward to upcoming readouts in our other ongoing trials.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9931048709,"gmtCreate":1662369048601,"gmtModify":1676537047156,"author":{"id":"3562115684410726","authorId":"3562115684410726","name":"KingCrab","avatar":"https://static.tigerbbs.com/405b64f3c681fc35136b02e8b5a53c12","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562115684410726","authorIdStr":"3562115684410726"},"themes":[],"htmlText":"I'm still bullish with this stock. China's supply comes online? Disruption of supply chain occurs each time China has a military drill around Taiwan. Besides, just wait for the next pandemic and this stock will sky-rocket again.","listText":"I'm still bullish with this stock. China's supply comes online? Disruption of supply chain occurs each time China has a military drill around Taiwan. Besides, just wait for the next pandemic and this stock will sky-rocket again.","text":"I'm still bullish with this stock. China's supply comes online? Disruption of supply chain occurs each time China has a military drill around Taiwan. Besides, just wait for the next pandemic and this stock will sky-rocket again.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9931048709","repostId":"2260170399","repostType":2,"repost":{"id":"2260170399","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1660881780,"share":"https://ttm.financial/m/news/2260170399?lang=&edition=fundamental","pubTime":"2022-08-19 12:03","market":"hk","language":"en","title":"Riverstone Holdings' Healthcare Gloves Segment Faces Headwinds -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2260170399","media":"Dow Jones","summary":"0401 GMT - Riverstone Holdings' healthcare gloves segment faces headwinds as additional supply begin","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0401 GMT - Riverstone Holdings' healthcare gloves segment faces headwinds as additional supply begins to come online, UOB Kay Hian analysts say in a research report as they lower the stock's target price to S$0.67 from S$0.80 with an unchanged hold rating. Average selling prices, or ASPs, of healthcare gloves fell roughly 10% on quarter in 2Q to around $28/1,000 pieces as demand normalized, and management said 3Q ASPs are likely to drop to prepandemic levels at $25/1,000 pieces, the analysts note. Together with weakening demand, more supply from China is expected to come on line in 3Q-4Q, creating downward pressure on ASPs, the analysts say. Shares are 0.7% higher at S$0.71. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 19, 2022 00:03 ET (04:03 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Riverstone Holdings' Healthcare Gloves Segment Faces Headwinds -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRiverstone Holdings' Healthcare Gloves Segment Faces Headwinds -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-08-19 12:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0401 GMT - Riverstone Holdings' healthcare gloves segment faces headwinds as additional supply begins to come online, UOB Kay Hian analysts say in a research report as they lower the stock's target price to S$0.67 from S$0.80 with an unchanged hold rating. Average selling prices, or ASPs, of healthcare gloves fell roughly 10% on quarter in 2Q to around $28/1,000 pieces as demand normalized, and management said 3Q ASPs are likely to drop to prepandemic levels at $25/1,000 pieces, the analysts note. Together with weakening demand, more supply from China is expected to come on line in 3Q-4Q, creating downward pressure on ASPs, the analysts say. Shares are 0.7% higher at S$0.71. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 19, 2022 00:03 ET (04:03 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AP4.SI":"立合斯顿","BK6511":"医疗保健服务概念","BK6103":"医疗保健用品"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2260170399","content_text":"0401 GMT - Riverstone Holdings' healthcare gloves segment faces headwinds as additional supply begins to come online, UOB Kay Hian analysts say in a research report as they lower the stock's target price to S$0.67 from S$0.80 with an unchanged hold rating. Average selling prices, or ASPs, of healthcare gloves fell roughly 10% on quarter in 2Q to around $28/1,000 pieces as demand normalized, and management said 3Q ASPs are likely to drop to prepandemic levels at $25/1,000 pieces, the analysts note. Together with weakening demand, more supply from China is expected to come on line in 3Q-4Q, creating downward pressure on ASPs, the analysts say. Shares are 0.7% higher at S$0.71. (ronnie.harui@wsj.com) \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 19, 2022 00:03 ET (04:03 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":274081223147728,"gmtCreate":1707952270413,"gmtModify":1707958449219,"author":{"id":"3562115684410726","authorId":"3562115684410726","name":"KingCrab","avatar":"https://static.tigerbbs.com/405b64f3c681fc35136b02e8b5a53c12","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562115684410726","authorIdStr":"3562115684410726"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/D05.SI\">$DBS GROUP HOLDINGS LTD(D05.SI)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/D05.SI\">$DBS GROUP HOLDINGS LTD(D05.SI)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$DBS GROUP HOLDINGS LTD(D05.SI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/274081223147728","isVote":1,"tweetType":1,"viewCount":67,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9954633055,"gmtCreate":1676300342478,"gmtModify":1676302498607,"author":{"id":"3562115684410726","authorId":"3562115684410726","name":"KingCrab","avatar":"https://static.tigerbbs.com/405b64f3c681fc35136b02e8b5a53c12","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562115684410726","authorIdStr":"3562115684410726"},"themes":[],"htmlText":"Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.","listText":"Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.","text":"Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9954633055","repostId":"2311278989","repostType":2,"repost":{"id":"2311278989","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1676291924,"share":"https://ttm.financial/m/news/2311278989?lang=&edition=fundamental","pubTime":"2023-02-13 20:38","market":"us","language":"en","title":"G1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2311278989","media":"Dow Jones","summary":"G1 Therapeutics Inc. said it has decided to discontinue its Phase 3 trial, called Preserve 1, that t","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/GTHX\">G1 Therapeutics Inc.</a> said it has decided to discontinue its Phase 3 trial, called Preserve 1, that tested trilaciclib administered along with triplet therapy with Folfoxiri and bevacizumab in patients with metastatic colorectal cancer.</p><p>Shares fell 55% to $3.2 in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/058bf0f8b0deeb4381b26c96de767e1e\" tg-width=\"838\" tg-height=\"840\" width=\"100%\" height=\"auto\"/></p><p>The company said the trial achieved its co-primary endpoints showing clinically meaningful reductions in severe neutropenia during induction, as well as in the average duration of severe neutropenia. Patients treated with trilaciclib also showed a reduction in the rate of chemotherapy-induced diarrhea, the company said.</p><p>However, early anti-tumor efficacy data favored patients in the placebo arm of the trial, the company said.</p><p>&#34;All of us at G1 are disappointed in this surprising outcome for patients with CRC, but we remain committed to the potential of trilaciclib to impact the lives of many cancer patients in other indications,&#34; G1 Chief Executive Jack Bailey said. &#34;We are increasingly encouraged by the real-world performance of trilaciclib in patients with extensive stage small cell lung cancer and look forward to upcoming readouts in our other ongoing trials.&#34;</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>G1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nG1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-02-13 20:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/GTHX\">G1 Therapeutics Inc.</a> said it has decided to discontinue its Phase 3 trial, called Preserve 1, that tested trilaciclib administered along with triplet therapy with Folfoxiri and bevacizumab in patients with metastatic colorectal cancer.</p><p>Shares fell 55% to $3.2 in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/058bf0f8b0deeb4381b26c96de767e1e\" tg-width=\"838\" tg-height=\"840\" width=\"100%\" height=\"auto\"/></p><p>The company said the trial achieved its co-primary endpoints showing clinically meaningful reductions in severe neutropenia during induction, as well as in the average duration of severe neutropenia. Patients treated with trilaciclib also showed a reduction in the rate of chemotherapy-induced diarrhea, the company said.</p><p>However, early anti-tumor efficacy data favored patients in the placebo arm of the trial, the company said.</p><p>&#34;All of us at G1 are disappointed in this surprising outcome for patients with CRC, but we remain committed to the potential of trilaciclib to impact the lives of many cancer patients in other indications,&#34; G1 Chief Executive Jack Bailey said. &#34;We are increasingly encouraged by the real-world performance of trilaciclib in patients with extensive stage small cell lung cancer and look forward to upcoming readouts in our other ongoing trials.&#34;</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4191":"家用电器","GTHX":"G1 Therapeutics Inc.","BK4539":"次新股","BK4007":"制药","BK4139":"生物科技","CRCT":"Cricut, Inc.","TERN":"Terns Pharmaceuticals, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2311278989","content_text":"G1 Therapeutics Inc. said it has decided to discontinue its Phase 3 trial, called Preserve 1, that tested trilaciclib administered along with triplet therapy with Folfoxiri and bevacizumab in patients with metastatic colorectal cancer.Shares fell 55% to $3.2 in premarket trading.The company said the trial achieved its co-primary endpoints showing clinically meaningful reductions in severe neutropenia during induction, as well as in the average duration of severe neutropenia. Patients treated with trilaciclib also showed a reduction in the rate of chemotherapy-induced diarrhea, the company said.However, early anti-tumor efficacy data favored patients in the placebo arm of the trial, the company said.\"All of us at G1 are disappointed in this surprising outcome for patients with CRC, but we remain committed to the potential of trilaciclib to impact the lives of many cancer patients in other indications,\" G1 Chief Executive Jack Bailey said. \"We are increasingly encouraged by the real-world performance of trilaciclib in patients with extensive stage small cell lung cancer and look forward to upcoming readouts in our other ongoing trials.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9931048709,"gmtCreate":1662369048601,"gmtModify":1676537047156,"author":{"id":"3562115684410726","authorId":"3562115684410726","name":"KingCrab","avatar":"https://static.tigerbbs.com/405b64f3c681fc35136b02e8b5a53c12","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562115684410726","authorIdStr":"3562115684410726"},"themes":[],"htmlText":"I'm still bullish with this stock. China's supply comes online? Disruption of supply chain occurs each time China has a military drill around Taiwan. Besides, just wait for the next pandemic and this stock will sky-rocket again.","listText":"I'm still bullish with this stock. China's supply comes online? Disruption of supply chain occurs each time China has a military drill around Taiwan. Besides, just wait for the next pandemic and this stock will sky-rocket again.","text":"I'm still bullish with this stock. China's supply comes online? Disruption of supply chain occurs each time China has a military drill around Taiwan. Besides, just wait for the next pandemic and this stock will sky-rocket again.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9931048709","repostId":"2260170399","repostType":2,"repost":{"id":"2260170399","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1660881780,"share":"https://ttm.financial/m/news/2260170399?lang=&edition=fundamental","pubTime":"2022-08-19 12:03","market":"hk","language":"en","title":"Riverstone Holdings' Healthcare Gloves Segment Faces Headwinds -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2260170399","media":"Dow Jones","summary":"0401 GMT - Riverstone Holdings' healthcare gloves segment faces headwinds as additional supply begin","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0401 GMT - Riverstone Holdings' healthcare gloves segment faces headwinds as additional supply begins to come online, UOB Kay Hian analysts say in a research report as they lower the stock's target price to S$0.67 from S$0.80 with an unchanged hold rating. Average selling prices, or ASPs, of healthcare gloves fell roughly 10% on quarter in 2Q to around $28/1,000 pieces as demand normalized, and management said 3Q ASPs are likely to drop to prepandemic levels at $25/1,000 pieces, the analysts note. Together with weakening demand, more supply from China is expected to come on line in 3Q-4Q, creating downward pressure on ASPs, the analysts say. Shares are 0.7% higher at S$0.71. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 19, 2022 00:03 ET (04:03 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Riverstone Holdings' Healthcare Gloves Segment Faces Headwinds -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRiverstone Holdings' Healthcare Gloves Segment Faces Headwinds -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-08-19 12:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0401 GMT - Riverstone Holdings' healthcare gloves segment faces headwinds as additional supply begins to come online, UOB Kay Hian analysts say in a research report as they lower the stock's target price to S$0.67 from S$0.80 with an unchanged hold rating. Average selling prices, or ASPs, of healthcare gloves fell roughly 10% on quarter in 2Q to around $28/1,000 pieces as demand normalized, and management said 3Q ASPs are likely to drop to prepandemic levels at $25/1,000 pieces, the analysts note. Together with weakening demand, more supply from China is expected to come on line in 3Q-4Q, creating downward pressure on ASPs, the analysts say. Shares are 0.7% higher at S$0.71. (ronnie.harui@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 19, 2022 00:03 ET (04:03 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AP4.SI":"立合斯顿","BK6511":"医疗保健服务概念","BK6103":"医疗保健用品"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2260170399","content_text":"0401 GMT - Riverstone Holdings' healthcare gloves segment faces headwinds as additional supply begins to come online, UOB Kay Hian analysts say in a research report as they lower the stock's target price to S$0.67 from S$0.80 with an unchanged hold rating. Average selling prices, or ASPs, of healthcare gloves fell roughly 10% on quarter in 2Q to around $28/1,000 pieces as demand normalized, and management said 3Q ASPs are likely to drop to prepandemic levels at $25/1,000 pieces, the analysts note. Together with weakening demand, more supply from China is expected to come on line in 3Q-4Q, creating downward pressure on ASPs, the analysts say. Shares are 0.7% higher at S$0.71. (ronnie.harui@wsj.com) \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 19, 2022 00:03 ET (04:03 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}